First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Colorectal Neoplasms
  • Deoxycytidine
  • Fluorouracil

abstract

  • Cetuximab plus capecitabine at a dose of 1,000 mg/m2 every 12 hours may be an alternative to more aggressive regimens in elderly patients with advanced wild-type KRAS CRC.

publication date

  • April 10, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3316919

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2011-0406

PubMed ID

  • 22363067

Additional Document Info

start page

  • 339

end page

  • 45

volume

  • 17

number

  • 3